Loading
A phase 2 trial of Daraxonrasib, Nivolumab, Temozolomide, PM8002, Pemetrexed and Carboplatin in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) is a phase 2 interventional study registered as NCT07492680 by Bristol-Myers Squibb, with 260 participants planned, started 2026-07-27 and due to reach its primary completion in 2028-08-15. Interventions recorded: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig and Pemetrexed.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Nivolumab and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Carboplatin and the tag pipeline.
Shares PM8002, Temozolomide, Bristol Myers Squibb and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/